Skip to main content
TipRanks
Go Ultimate75% OFF

Corvus Pharmaceuticals (CRVS) AI Stock Analysis

715 Followers
CRVS

Corvus Pharmaceuticals

(NASDAQ:CRVS)

Select Model
Rating:51Neutral
Price Target:$10.00â–¼(-1.67% Downside)
Action:reiterated
Date:11/06/26

The score is held back primarily by weak financial performance (no meaningful revenue, recurring losses, and significant cash burn) and bearish technicals (trading below major moving averages with negative momentum). These are partially offset by a strong balance sheet with very low leverage and a constructive earnings call outlook, including runway into Q2 2028 and multiple expected 2027 clinical catalysts, though the PTCL futility check remains a notable near-term risk.

Positive Factors
Extended Cash RunwayThe cash position provides Corvus with a meaningful operating runway through the second quarter of 2028 under current plans. This reduces immediate financing pressure and allows the company to advance several clinical programs toward important readouts before additional capital may be needed.
Negative Factors
No Meaningful RevenueCorvus remains dependent on clinical development rather than commercial product revenue, leaving its business model without established recurring sales support. Until a candidate is successfully developed and commercialized, profitability and durable operating traction remain unproven.

Corvus Pharmaceuticals (CRVS) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%CRVS+19.51%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$894.14M
Dividend Yield
―
Average Volume (3M)
1.04M
Price to Earnings (P/E)
-13.9
Beta (1Y)
1.00
Revenue Growth
―
EPS Growth
-272.40%
Country
US
Employees
37
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Corvus Pharmaceuticals Business Overview & Revenue Model

Company Description

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibod...

Corvus Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:4.52%|Next Earnings Date:Mar 24, 2027
Earnings Call SentimentPositive

The call was predominantly positive, with enrollment on track or ahead of plan across multiple programs, favorable early ALPS results, a strong cash position extending the operating runway into the second quarter of 2028, and several clinical milestones expected in 2027. The main negatives were increased R&D spending, a wider net loss, higher stock compensation, the modest extension of Angel's data timing, and the possibility that the PTCL trial could be stopped for futility.

Positive Updates

Strong Cash Position and Extended Operating Runway
Cash, cash equivalents and marketable securities totaled $202.9 million as of September 30, 2026, compared with $56.8 million at December 31, 2025. The balance included approximately $189.4 million in net proceeds from a follow-on offering completed in Q1. Based on its cash position and current plans, Corvus expects cash to fund operations into the second quarter of 2028.

Negative Updates

Higher Research and Development Expenses
Third-quarter 2026 R&D expenses increased to $17.8 million from $8.5 million in the same period of 2025. Management attributed the increase primarily to higher clinical trial costs associated with soquelitinib development and higher personnel costs.

Company Guidance

Based on cash, cash equivalents and marketable securities of $202.9 million as of September 30, 2026, Corvus expects its cash to fund operations into the second quarter of 2028; the Phase 3 PTCL futility analysis is anticipated in the first quarter of 2027 and top line data before the end of the year 2027, while SEERA-1 was planned to enroll approximately 200 patients across 3 soquelitinib doses and a placebo group with top line data anticipated in the third quarter of 27 and a potential Phase III start in 2028; ANGEL cohort 2 is expected to begin enrolling in November, with cohort 2 data potentially available in the second half of 2027, and an additional 60 to 90 patients anticipated in the Phase 2 portion; the HS Phase 1b trial is designed to enroll up to 25 patients and may report data in the first half of 2027; Corvus is on track to initiate the asthma trial in the first quarter of 2027, and both Corvus and Angel plan to launch asthma trials in 2027.

Corvus Pharmaceuticals Financial Statement Overview

Summary

Financials reflect an early-stage biotech profile: essentially no revenue, recurring operating losses, and worsening TTM net loss alongside deeply negative operating/free cash flow. The main offset is a strong, low-leverage balance sheet (very low debt vs. sizable equity), which supports resilience but does not remove ongoing burn/financing risk.

Income Statement

12Very Negative

Balance Sheet

66Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-26.00K-105.00K0000
EBITDA-61.93M-15.18M-62.21M-26.88M-40.94M-42.77M
Net Income-64.31M-15.28M-62.29M-27.03M-41.31M-43.24M
Balance Sheet
Total Assets223.88M71.12M68.91M45.55M68.24M109.45M
Cash, Cash Equivalents and Short-Term Investments202.95M56.75M51.96M27.15M42.30M69.45M
Total Debt632.00K937.00K1.12M1.37M2.60M3.65M
Total Liabilities15.56M9.91M36.34M6.87M12.13M12.29M
Stockholders Equity208.32M61.20M32.57M38.68M56.12M97.16M
Cash Flow
Free Cash Flow-47.94M-32.97M-25.42M-23.97M-27.29M-36.72M
Operating Cash Flow-47.18M-32.80M-25.42M-23.93M-27.02M-36.72M
Investing Cash Flow-132.41M-7.80M-27.48M15.54M-23.28M21.56M
Financing Cash Flow191.74M36.43M49.03M7.86M062.16M

Corvus Pharmaceuticals Technical Analysis

Technical Analysis SentimentNegative
Last Price10.17

Price Trends

50DMA11.03Negative
100DMA12.73Negative
200DMA13.89Negative

Market Momentum

MACD-0.07Negative
RSI44.54Neutral
STOCH38.79Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVS, the sentiment is Negative. The current price of 10.17 is below the 20-day moving average (MA) of 10.48, below the 50-day MA of 11.03, and below the 200-day MA of 13.89, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 44.54 is Neutral, neither overbought nor oversold. The STOCH value of 38.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRVS.

Corvus Pharmaceuticals Risk Analysis

Corvus Pharmaceuticals disclosed 73 risk factors in its most recent earnings report. Corvus Pharmaceuticals reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Beginning January 1, 2027, we will no longer qualify as a smaller reporting company, which will increase our costs and demands on management, which will be further increased if and when we lose our status as a non-accelerated filer and become subject to auditor attestation requirements.Q3, 2026
2.Beginning January 1, 2027, we will no longer qualify as a smaller reporting company, which will increase our costs and demands on management, which will be further increased if and when we lose our status as a non-accelerated filer and become subject to auditor attestation requirements.Q2, 2026
3.Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.Q4, 2023

Corvus Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CRVS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
XNCRXNCR61Neutral$2.59B-22.05-21.29%―33.55%11.51%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CRVSCRVS51Neutral$857.87M-13.86-34.98%――-272.40%
KURAKURA48Neutral$688.17M-2.26-336.24%―-23.76%-33.09%
IMTXIMTX46Neutral$941.21M-3.33-52.19%―-44.50%-80.18%
CTMXCTMX44Neutral$422.93M-4.28-33.97%―-87.66%-210.45%
ORICORIC44Neutral$831.45M-5.35-40.99%――15.37%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%CRVSXNCRCTMXKURAORICIMTXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CRVS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CRVSCorvus Pharmaceuticals Inc.10.171.2714.27%
XNCRXencor Inc.34.5018.73118.77%
CTMXCytomX Therapeutics Inc.1.94-1.69-46.56%
KURAKura Oncology7.49-3.83-33.83%
ORICOric Pharmaceuticals Inc8.00-3.48-30.31%
IMTXImmatics N.V.6.29-4.04-39.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026